CA3225436A1 - Methode de regulation de l'expression genique - Google Patents
Methode de regulation de l'expression genique Download PDFInfo
- Publication number
- CA3225436A1 CA3225436A1 CA3225436A CA3225436A CA3225436A1 CA 3225436 A1 CA3225436 A1 CA 3225436A1 CA 3225436 A CA3225436 A CA 3225436A CA 3225436 A CA3225436 A CA 3225436A CA 3225436 A1 CA3225436 A1 CA 3225436A1
- Authority
- CA
- Canada
- Prior art keywords
- csf
- catheter
- pump
- ventricle
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 95
- 230000014509 gene expression Effects 0.000 title claims abstract description 13
- 230000001105 regulatory effect Effects 0.000 title claims description 10
- 239000012530 fluid Substances 0.000 claims abstract description 87
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 55
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 55
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 55
- 239000000463 material Substances 0.000 claims abstract description 55
- 230000008878 coupling Effects 0.000 claims abstract description 25
- 238000010168 coupling process Methods 0.000 claims abstract description 25
- 238000005859 coupling reaction Methods 0.000 claims abstract description 25
- 210000004556 brain Anatomy 0.000 claims abstract description 19
- 210000004705 lumbosacral region Anatomy 0.000 claims abstract description 19
- 230000008569 process Effects 0.000 claims description 44
- 230000001276 controlling effect Effects 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 abstract description 13
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 238000009826 distribution Methods 0.000 abstract description 3
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 210000000578 peripheral nerve Anatomy 0.000 abstract description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 165
- 229940079593 drug Drugs 0.000 description 74
- 239000003814 drug Substances 0.000 description 74
- 238000007726 management method Methods 0.000 description 27
- 230000001225 therapeutic effect Effects 0.000 description 20
- 210000003484 anatomy Anatomy 0.000 description 16
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 229960000485 methotrexate Drugs 0.000 description 11
- 238000012377 drug delivery Methods 0.000 description 10
- 210000002330 subarachnoid space Anatomy 0.000 description 10
- 238000001802 infusion Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241001494479 Pecora Species 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000002457 bidirectional effect Effects 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 230000010355 oscillation Effects 0.000 description 4
- 230000000541 pulsatile effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003140 lateral ventricle Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 2
- 101150049278 US20 gene Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- -1 antibodies Proteins 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000012539 chromatography resin Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- POYODSZSSBWJPD-UHFFFAOYSA-N 2-methylprop-2-enoyloxy 2-methylprop-2-eneperoxoate Chemical compound CC(=C)C(=O)OOOC(=O)C(C)=C POYODSZSSBWJPD-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101001072091 Homo sapiens ProSAAS Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 240000003888 Phoenix reclinata Species 0.000 description 1
- 102100036366 ProSAAS Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101150110932 US19 gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003703 cisterna magna Anatomy 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000005404 magnetometry Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000012576 optical tweezer Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010384 proximity ligation assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M27/006—Cerebrospinal drainage; Accessories therefor, e.g. valves
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une méthode de régulation de l'expression génique d'un patient par la circulation contrôlée d'une matière d'oligonucléotide antisens (ASO) à travers un circuit de fluide fermé formé entre le ventricule du patient et les régions lombaires. À cet effet, après le couplage d'un canal de fluide entre ces régions, de tels modes de réalisation ajoutent de l'ASO au canal de fluide (de préférence après que le canal a été amorcé avec du CSF) et activent une pompe pour faire circuler de manière contrôlée le CSF et l'ASO mélangé au CSF. Le flux de fluide CSF/ASO peut être géré pour localiser un traitement (par exemple, fournir une distribution cérébrale profonde) tout en réduisant au minimum la toxicité potentiellement provoquée par l'ASO vers certains nerfs (par exemple, le nerf périphérique).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214239P | 2021-06-23 | 2021-06-23 | |
| US63/214,239 | 2021-06-23 | ||
| PCT/US2022/034706 WO2022271938A1 (fr) | 2021-06-23 | 2022-06-23 | Méthode de régulation de l'expression génique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3225436A1 true CA3225436A1 (fr) | 2022-12-29 |
Family
ID=84544860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3225436A Pending CA3225436A1 (fr) | 2021-06-23 | 2022-06-23 | Methode de regulation de l'expression genique |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4359054A1 (fr) |
| AU (1) | AU2022297513A1 (fr) |
| CA (1) | CA3225436A1 (fr) |
| WO (1) | WO2022271938A1 (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197300B1 (en) * | 1997-08-12 | 2001-03-06 | Smithkline Beecham Corporation | ftsZ |
| BR9812650A (pt) * | 1997-09-17 | 2000-08-22 | Univ East Carolina | ácidos nucléicos hibridizando marcação múltipla, preparação dos mesmos, composições, formulação, kits e aplicações |
| EP1135113B1 (fr) * | 1998-11-05 | 2008-10-01 | Thomas Jefferson University | Traitement de la maladie de parkinson avec des oligonucleotides |
| WO2017117138A1 (fr) * | 2015-12-28 | 2017-07-06 | Cognost Therapeutics Inc. | Appareil et procédé de micro-dialyse cérébrale pour le traitement de maladie neurologique, notamment la maladie d'alzheimer, la maladie de parkinson ou la sclérose en plaques |
| CA3013898A1 (fr) * | 2016-02-04 | 2017-08-10 | Zhenglun Zhu | Traitement et diagnostic de troubles inflammatoires |
| AU2020271894A1 (en) * | 2019-04-11 | 2021-12-02 | Enclear Therapies, Inc. | Methods of amelioration of cerebrospinal fluid and devices and systems therefor |
-
2022
- 2022-06-23 WO PCT/US2022/034706 patent/WO2022271938A1/fr active Application Filing
- 2022-06-23 EP EP22829302.3A patent/EP4359054A1/fr active Pending
- 2022-06-23 AU AU2022297513A patent/AU2022297513A1/en active Pending
- 2022-06-23 CA CA3225436A patent/CA3225436A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4359054A1 (fr) | 2024-05-01 |
| AU2022297513A1 (en) | 2024-01-18 |
| WO2022271938A9 (fr) | 2023-12-07 |
| WO2022271938A1 (fr) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11577060B2 (en) | Systems and methods for the conditioning of cerebrospinal fluid | |
| US10695545B2 (en) | Systems and methods for the conditioning of cerebrospinal fluid | |
| EP2133108B1 (fr) | Dispositif d'administration de médicaments libérant des médicaments d'une manière pulsative | |
| CN114007665A (zh) | 改善脑脊液的方法及其装置和系统 | |
| AU2021357810A1 (en) | System and method for controlling csf flow and managing intracranial pressure | |
| US20220313890A1 (en) | Method of regulating gene expression | |
| US20220096745A1 (en) | Subarachnoid fluid conduit system and kit | |
| CA3225436A1 (fr) | Methode de regulation de l'expression genique | |
| CN116471981A (zh) | 蛛网膜下流体管理方法和系统 | |
| US20220355015A1 (en) | Csf diagnostics platform | |
| US20230321412A1 (en) | System and method for managing cancer cells in csf | |
| WO2023003888A1 (fr) | Plateforme de diagnostic du liquide céphalorachidien (lcr) | |
| US20230355118A1 (en) | System and method for monitoring physiological parameters based on cerebrospinal fluid pressures taken at two or more locations |